Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread.

A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative ...

Significantly longer progression-free survival seen among patients with previously untreated, PD-L1 advanced or metastatic ...

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

We conducted a retrospective cohort study of patients with TNBC treated between 2010 and 2019. Overall survival (OS) rates by stage were analyzed across various patient groups, including those ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies.